Review decision date: October 2013

Review decision: 

The guideline should not be updated at this time. For further information, please refer to surveillance review decision.

This guideline will shortly be checked to see if it needs updating, please register as a stakeholder to be informed about the decision.

Register as a stakeholder

Next review date: August 2016

This guidance updates and replaces NICE guideline CG18 (published August 2004) and NICE guideline CG34 (published June 2006).

It offers evidence-based advice on the care and treatment of adults with primary hypertension. New and updated recommendations on diagnosis, antihypertensive drug treatment and treatment monitoring were included in 2011.

Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

  • National Institute for Health and Care Excellence (NICE) accreditation logo